Emerging role of multikinase inhibitors for refractory thyroid cancer

  title={Emerging role of multikinase inhibitors for refractory thyroid cancer},
  author={Cesar Augusto Perez and Belisario A. Arango and Michel Velez and Luis E Raez and Edgardo S. Santos},
  booktitle={Biologics : targets & therapy},
Thyroid cancer incidence continues to increase, remaining the most common endocrine malignancy. The need for effective systemic therapies combined with high incidence of driver mutations and overexpression of molecular pathways make refractory thyroid cancer an ideal candidate for treatment with novel agents. Multikinase inhibitors have caused a paradigm shift in the treatment of patients with advanced iodine-refractory thyroid cancer. These agents have shown to be the most effective systemic… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS


Publications referenced by this paper.
Showing 1-10 of 56 references

Phase 2 study of sunitinib in refractory thyroid cancer [abstract

  • EE Cohen, BM Needles, KJ Cullen
  • J Clin Oncol
  • 2008
Highly Influential
4 Excerpts

Similar Papers

Loading similar papers…